Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000542876 | SCV000648599 | likely benign | Neuroblastoma, susceptibility to, 3 | 2024-01-08 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000542876 | SCV000897006 | uncertain significance | Neuroblastoma, susceptibility to, 3 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002255453 | SCV002528380 | likely benign | Hereditary cancer-predisposing syndrome | 2021-11-25 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV002255453 | SCV002635951 | likely benign | Hereditary cancer-predisposing syndrome | 2022-01-04 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV004772982 | SCV005387182 | uncertain significance | not provided | 2024-04-26 | criteria provided, single submitter | clinical testing | In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; This variant is associated with the following publications: (PMID: 27397505, 25714698, 35865984) |